GT
ERAS icon

Glenmede Trust’s Erasca ERAS Stock Holding History

Glenmede Trust’s Portfolio ERAS Stock Details ERAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$734K Buy
+40,085
New +$573K ﹤0.01% 866

Other funds holding ERAS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Glenmede Trust's ERAS Position: Q2 2026 in Review

Glenmede Trust opened a new position in Erasca (ERAS) in Q2 2026: 40,085 shares worth $734K. The stake represents ﹤0.01% of the portfolio and ranks #866 among its holdings.

257 funds tracked by Wall St. Rank hold ERAS as of Q2 2026.

  • Glenmede Trust held 40,085 shares of Erasca worth $734K as of Q2 2026.
  • Erasca was a new Glenmede Trust position in Q2 2026.
  • Erasca made up ﹤0.01% of Glenmede Trust's portfolio in Q2 2026, its #866 holding.
  • 257 funds tracked by Wall St. Rank held Erasca as of Q2 2026.

Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.